Table 9.
Cost-effectiveness of expanded hepatitis B virus treatment in high and low-income countries
|
Ref.
|
Country
|
Expanded HBV treatment criteria
|
ICER/DALY averted
|
Cost-effectiveness threshold1
|
| Razavi-Shearer et al[71], 2023 |
United States | Treat all | $41700 | $65850 |
| Sanai et al[72], 2020 | Saudi Arabia | Treat all | $22500 | $66150 |
| Lim et al[73], 2022 | Korea | Simplified algorithm (only HBV DNA) | $25832 | $22000 |
| Crossan et al[74], 2016 | United Kingdom | Treat all | £28137 | £20000 |
| Nguyen et al[75], 2024 | The Gambia | Treat all | $2149 | $352 |
1
Cost effectiveness threshold: 0.5 × per capita GDP.
2
Simplified algorithm (only DNA, no alanine aminotransferase, hepatitis B e antigen).
ICER: Incremental cost-effectiveness ratio; DALY: Disability-adjusted life year; HBV: Hepatitis B virus.